J. Robinson

发表

Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory.

Jennifer G. Robinson, Shelley A. Rusincovitch, R. Califf, 2013, Journal of the American Medical Informatics Association : JAMIA.

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Jennifer G. Robinson, D. DeMets, Jeffrey L. Anderson, 2014, Circulation.

Human Nutrition and Metabolism Soy Protein Intake by Perimenopausal Women Does Not Affect Circulating Lipids and Lipoproteins or Coagulation and Fibrinolytic Factors 1 , 2

Jennifer G. Robinson, J. Robinson, M. Reddy, 2001 .

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Jennifer G. Robinson, D. DeMets, R. D'Agostino, 2014, Circulation.

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Jennifer G. Robinson, R. D'Agostino, R. Gibbons, 2014, Circulation.

A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure.

Fernando Pires Hartwig, Claude Bouchard, Christian Gieger, 2018, American journal of human genetics.

Evidence-Based Policy Making: Assessment of the American Heart Association’s Strategic Policy Portfolio A Policy Statement From the American Heart Association

Jennifer G. Robinson, E. Antman, A. Khera, 2016, Circulation.

Evaluation of the Metabochip Genotyping Array in African Americans and Implications for Fine Mapping of GWAS-Identified Loci: The PAGE Study

Jennifer G. Robinson, C. Carlson, T. Assimes, 2012, PloS one.

Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

Jennifer G. Robinson, P. Wilson, R. Eckel, 2013, Journal of the American Pharmacists Association : JAPhA.

Sleep duration, cognitive decline, and dementia risk in older women

Jennifer G. Robinson, J. Manson, Karen C Johnson, 2016, Alzheimer's & Dementia.

Reply: 2013 ACC/AHA guideline on the assessment of cardiovascular risk.

Jennifer G. Robinson, R. D'Agostino, R. Gibbons, 2014, Journal of the American College of Cardiology.

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Jennifer G. Robinson, John J. Connolly, J. Gallacher, 2012, The Lancet.

Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol.

Jennifer G. Robinson, Kyle J. Gaulton, Emily H Turner, 2014, American journal of human genetics.

Relationship of Hypertension, Blood Pressure, and Blood Pressure Control With White Matter Abnormalities in the Women’s Health Initiative Memory Study (WHIMS)—MRI Trial

Jennifer G. Robinson, Lewis H Kuller, Diana Kerwin, 2010, Journal of clinical hypertension.

Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks.

Jennifer G. Robinson, C. Carlson, R. Marioni, 2014, American journal of human genetics.

Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women.

Jennifer G. Robinson, Charles Kooperberg, Hua Tang, 2012, American journal of human genetics.

Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained

Jennifer G. Robinson, D. Absher, T. Assimes, 2013, PLoS genetics.

ARTICLE Genome-wide Characterization of Shared and Distinct Genetic Components that Influence Blood Lipid Levels in Ethnically Diverse Human Populations

Xiaofeng Zhu, Charles Kooperberg, Nicholas A. Johnson, 2022 .

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

He Zhang, Thomas Meitinger, Raimund Erbel, 2014, The New England journal of medicine.

Fine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci.

Jennifer G. Robinson, M. Fornage, D. Absher, 2016, Human molecular genetics.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Szilard Voros, Jennifer G. Robinson, Brian A Ference, 2016, The New England journal of medicine.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Hynek Pikhart, Bengt Sennblad, Tom R. Gaunt, 2015, The Lancet.

Reprint: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.

Judith S. Hochman, Jennifer G. Robinson, Lesley H. Curtis, 2013, Journal of the American Pharmacists Association : JAPhA.

Management of Elevated Low-Density Lipoprotein Cholesterol

Jennifer G. Robinson, J. Robinson, M. Davidson, 2006 .

Clinical Trials Targeting Aging and Age-Related Multimorbidity

Jennifer G. Robinson, J. Manson, S. Kritchevsky, 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure.

Jennifer G. Robinson, Nicholette D. Palmer, Blair H. Smith, 2019, Human molecular genetics.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Jennifer G. Robinson, Patrick McBride, Karol Watson, 2014, Journal of the American College of Cardiology.

Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.

Jennifer G. Robinson, J. Hartikainen, J. Robinson, 2017, Journal of the American College of Cardiology.

The next treatment paradigm in cardiovascular prevention?

Jennifer G. Robinson, J. Robinson, 2019, The Lancet.

Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women’s Health Initiative

Jennifer G. Robinson, T. Assimes, J. Manson, 2014, Circulation. Cardiovascular quality and outcomes.

Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association

Michael Miller, E. Rimm, L. Appel, 2017, Circulation.

Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease.

Jennifer G. Robinson, J. Robinson, P. Kris-Etherton, 2018, Journal of clinical lipidology.

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

How low to target LDL?

Jennifer G. Robinson, J. Robinson, M. Davidson, 2006, Nature Clinical Practice Endocrinology &Metabolism.

Managing cholesterol in the elderly

Jennifer G. Robinson, J. Robinson, M. Davidson, 2006 .

Low LDL-C Levels: Likely No Short-Term Cognitive Harm.

Jennifer G. Robinson, J. Robinson, 2020, Journal of the American College of Cardiology.

Lipid-lowering effects of ezetimibe & simvastatin in combination Drug Profile Pharmacokinetics

Jennifer G. Robinson, J. Robinson, N. Ijioma, 2011 .

Embedding clinical interventions into observational studies.

Jennifer G. Robinson, L. Kuller, A. Newman, 2016, Contemporary clinical trials.

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Jennifer G. Robinson, J. Robinson, E. Stroes, 2020, Cardiology and Therapy.

Evidence-based public health: an evolving concept.

Jennifer G. Robinson, J. Torner, J. Robinson, 2004, American journal of preventive medicine.

Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Jennifer G. Robinson, Lawrence J. Fine, J. Hsia, 2014, JAMA internal medicine.

10-year CVD risk prediction and minimization via InverseClassification

Chen Yang, William Nick Street, Jennifer G. Robinson, 2012, IHI '12.

Association of body mass index with colorectal cancer risk by genome-wide variants.

Jennifer G. Robinson, Stephanie A. Bien, H. Brenner, 2020, Journal of the National Cancer Institute.

Multi-ancestry genome-wide association study accounting for gene-psychosocial factor interactions identifies novel loci for blood pressure traits

Jennifer G. Robinson, M. Fornage, C. Gieger, 2020, HGG advances.

Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions

Jennifer G. Robinson, Nicholette D. Palmer, Christine A. Williams, 2019 .

Impact of Cyclooxygenase Inhibitors in the Women's Health Initiative Hormone Trials: Secondary Analysis of a Randomized Trial

Jennifer G. Robinson, J. Manson, R. Langer, 2006, PLoS clinical trials.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.

Jennifer G. Robinson, N. Sattar, J. Robinson, 2016, The lancet. Diabetes & endocrinology.

Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.

Jennifer G. Robinson, W. Hsueh, J. Robinson, 2013, Journal of clinical lipidology.

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from th

Jennifer G. Robinson, W. Hsueh, J. Robinson, 2011, Journal of clinical lipidology.

Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.

Jennifer G. Robinson, J. Robinson, K. Fox, 2015, Atherosclerosis.

Is it over for ezetimibe?

Jennifer G. Robinson, J. Robinson, M. Davidson, 2008, Expert review of cardiovascular therapy.

Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear

Jennifer G. Robinson, J. Robinson, H. Schrott, 2007, Cardiovascular Drugs and Therapy.

Development of a comprehensive health-risk prediction tool for postmenopausal women

Jennifer G. Robinson, J. Cauley, H. Hedlin, 2019, Menopause.

Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials

Jennifer G. Robinson, J. Hsia, L. Kuller, 2008, Arteriosclerosis, thrombosis, and vascular biology.

Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).

Jennifer G. Robinson, J. Robinson, R. Wallace, 2008, The American journal of cardiology.

Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.

Jennifer G. Robinson, J. Manson, J. Hsia, 2006, American heart journal.

Multimarker prediction of coronary heart disease risk: the Women's Health Initiative.

Jennifer G. Robinson, Philip Greenland, JoAnn E Manson, 2010, Journal of the American College of Cardiology.

Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative

Jennifer G. Robinson, Nancy R Cook, Nina P Paynter, 2012, Circulation.

Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women’s Health Initiative

Jennifer G. Robinson, H. Hedlin, J. Robinson, 2015, Circulation. Cardiovascular quality and outcomes.

Racial/Ethnic and Gender Gaps in the Use of and Adherence to Evidence-Based Preventive Therapies Among Elderly Medicare Part D Beneficiaries After Acute Myocardial Infarction

Jennifer G. Robinson, J. Robinson, C. Oramasionwu, 2014, Circulation.

Cardiovascular Health and Incident Cardiovascular Disease and Cancer: The Women's Health Initiative.

Jennifer G. Robinson, L. Hou, L. Kuller, 2016, American journal of preventive medicine.

Serum lipid changes following the onset of depressive symptoms in postmenopausal women

Jennifer G. Robinson, J. Robinson, M. Payne, 2017, Psychiatry Research.

How delayed treatment benefits and harms would impact the optimal timing of statin initiation for cardiovascular primary prevention

Jennifer G. Robinson, Greggory J. Schell, Mariel S. Lavieri, 2019, bioRxiv.

Fatty acid consumption and risk of fracture in the Women's Health Initiative.

Jennifer G. Robinson, J. Cauley, F. Tylavsky, 2010, The American journal of clinical nutrition.

Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies

Jennifer G. Robinson, D. Mozaffarian, F. Hu, 2018, PLoS medicine.

Low Birth Weight and Risk of Later-Life Physical Disability in Women

Jennifer G. Robinson, Cassandra N. Spracklen, S. Anton, 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation: The Women’s Health Initiative Randomized Controlled Trials

Paul J. Wang, J. Manson, M. Perez, 2012, Circulation. Arrhythmia and electrophysiology.

A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients.

Jennifer G. Robinson, J. Robinson, W. S. St. Peter, 2020, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia

Jennifer G. Robinson, D. Mozaffarian, P. Shi, 2022, JAMA network open.

Long-Term Trends in Hypertension and Elevated Blood Pressure Among U.S. Adults, 1999 to 2016.

Jennifer G. Robinson, L. Snetselaar, J. Robinson, 2018, Journal of the American College of Cardiology.

Calcium/vitamin D supplementation, serum 25-hydroxyvitamin D concentrations, and cholesterol profiles in the Women’s Health Initiative calcium/vitamin D randomized trial

Jennifer G. Robinson, J. Manson, S. Kritchevsky, 2014, Menopause.

Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative.

Jennifer G. Robinson, J. Robinson, T. Rohan, 2010, The American journal of clinical nutrition.

Criteria for Total Cholesterol and Low-Density Lipoprotein Cholesterol for the Diagnosis of Probable Heterozygous Familial Hypercholesterolemia ( HeFH ) a

Jennifer G. Robinson, J. Robinson, 2013 .

Longitudinal Study of Low Serum LDL and Depressive Symptom Onset in Postmenopause

Jennifer G. Robinson, W. Coryell, J. Robinson, 2016 .

Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment.

Jennifer G. Robinson, W. Ambrosius, J. Robinson, 2006, The American journal of cardiology.

Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial.

Jennifer G. Robinson, J. Manson, R. Prentice, 2017, The American journal of clinical nutrition.

Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction

J. Robinson, R. Wallace, E. Letuchy, 2016, Journal of the American Geriatrics Society.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

Jennifer G. Robinson, C. Cannon, J. Robinson, 2015, American heart journal.

Writing Group ( list individual with lead responsibility first ) : ( lead )

A. Folsom, M. Szklo, J. Robinson, 2000 .

Chart validation of inpatient ICD‐9‐CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database

Jennifer G. Robinson, Charles E. Leonard, J. Robinson, 2018, Pharmacoepidemiology and drug safety.

Restingheartrateasalowtechpredictorofcoronaryevents in women: prospective cohort study

Jennifer G. Robinson, J. Manson, A. LaCroix, 2009 .

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Jennifer G. Robinson, D. Gaudet, G. Watts, 2017, The American journal of cardiology.

Association of Low‐Density Lipoprotein Cholesterol Levels with More than 20‐Year Risk of Cardiovascular and All‐Cause Mortality in the General Population

Jennifer G. Robinson, J. Robinson, Buyun Liu, 2022, Journal of the American Heart Association.

Comparison of effectiveness and safety of simvastatin in patients <75 versus > or =75 years of age with coronary, cerebral, or peripheral arterial disease.

Jennifer G. Robinson, J. Robinson, W. Wickemeyer, 2002, The American journal of cardiology.

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Tom R. Gaunt, Aroon D. Hingorani, J. Gallacher, 2015, The Lancet.

Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies

Jennifer G. Robinson, D. Mozaffarian, F. Hu, 2021, Nature Communications.

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.

Jennifer G. Robinson, J. Robinson, H. Bays, 2016, The American journal of cardiology.

Treatment of Adults with Familial Hypercholesterolemia

J. Robinson, 2011 .

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

J. Mckenney, C. Cannon, J. Robinson, 2016, Journal of clinical lipidology.

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.

C. Cannon, M. Taskinen, J. Kastelein, 2019, Journal of clinical lipidology.

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2years

J. Robinson, W. Sasiela, H. Colhoun, 2018 .

Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50-54 years: Results from the Women's Health Initiative Memory Study of Younger Women (WHIMSY)

J. Manson, S. Resnick, J. Robinson, 2013, Alzheimer's & Dementia.

Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study.

Jennifer G. Robinson, J. Manson, J. Robinson, 2017, Journal of clinical lipidology.

Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study

Jennifer G. Robinson, L. Snetselaar, J. Robinson, 2019, British Medical Journal.

Meta-analysis of LDL-C Lowering and Mortality-Reply.

Jennifer G. Robinson, J. Robinson, F. Andreotti, 2018, JAMA.

Does comorbidity matrix provide similar amount of predictive information: Comparisons from Charlson and Elixhauser using Deep Learning

Jennifer G. Robinson, P. Tonellato, J. Robinson, 2022, 2022 IEEE 10th International Conference on Healthcare Informatics (ICHI).

PCSK9 Inhibitors and Cardiovascular Events.

Jennifer G. Robinson, J. Robinson, J. Kastelein, 2015, The New England journal of medicine.

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes

Jennifer G. Robinson, J. Robinson, F. Raal, 2015 .

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

Jennifer G. Robinson, M. Krempf, J. Robinson, 2014, Cardiovascular Drugs and Therapy.

Comparison of Lifestyle Based to Traditional CVD Prediction in a Multiethnic Cohort of Non-Smoking Women

Jennifer G. Robinson, J. Manson, N. Paynter, 2014 .

Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Jennifer G. Robinson, Lawrence A Leiter, J. Fleg, 2016, The American journal of medicine.

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Jennifer G. Robinson, S. Daniels, D. Rader, 2011, Journal of clinical lipidology.

Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Jennifer G. Robinson, J. Robinson, A. Goldberg, 2011, Journal of clinical lipidology.

n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies

Jennifer G. Robinson, W. Guan, D. Mozaffarian, 2021, Diabetes Care.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Jennifer G. Robinson, M. Krempf, G. Luc, 2015, The New England journal of medicine.

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?

Jennifer G. Robinson, G. Bakris, J. Torner, 2007, Stroke.

Response to Letter Regarding Article, "Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative"

Jennifer G. Robinson, J. Manson, K. Matthews, 2010, Circulation.

Lack of Association Between 25(OH)D Levels and Incident Type 2 Diabetes in OlderWomen

Jennifer G. Robinson, J. Manson, B. Howard, 2011 .

The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study

Jennifer G. Robinson, J. Robinson, F. Stapleton, 2016, British Journal of Ophthalmology.

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.

Jennifer G. Robinson, J. Robinson, W. Sasiela, 2017, Journal of the American College of Cardiology.

Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction

Jennifer G. Robinson, J. Robinson, M. Schroeder, 2022, Pharmacy.

Starting primary prevention earlier with statins.

Jennifer G. Robinson, J. Robinson, 2014, The American journal of cardiology.

Determining When to Add Nonstatin Therapy: A Quantitative Approach.

Jennifer G. Robinson, M. Pencina, J. Robinson, 2016, Journal of the American College of Cardiology.

Reply: Cost Effectiveness of Nonstatin-to-Statin Therapy.

J. Robinson, 2017, Journal of the American College of Cardiology.

Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group

Jennifer G. Robinson, K. Matthews, B. Spring, 2020, Journal of the American Heart Association.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Jennifer G. Robinson, J. Robinson, Ping Xu, 2013, Journal of the American College of Cardiology.

Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements

Jennifer G. Robinson, B. Howard, J. Robinson, 2008, Clinical trials.

Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative

Jennifer G. Robinson, J. Manson, R. Langer, 2010, Menopause.

ACCF/AHA TASK FORCE MEMBERS

Jennifer G. Robinson, R. Gibbons, D. Goff, 2013 .

Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American Pharmacists Association, American Society for Preventive Cardiology, Association of Black Cardiologists, Preventive Cardiovascular Nurses Association, and WomenHeart: The National Coalition for Women with H

Jennifer G. Robinson, R. Eckel, D. Gordon, 2013 .

Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport

Jennifer G. Robinson, J. Robinson, M. Davidson, 2007 .

A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.

Jennifer G. Robinson, J. Robinson, N. Maheshwari, 2005, The American journal of cardiology.

Birth weight and subsequent risk of cancer.

Jennifer G. Robinson, Cassandra N. Spracklen, L. Hou, 2014, Cancer epidemiology.

Omega‐3 fatty acid biomarkers and subsequent depressive symptoms

J. Manson, W. Coryell, J. Robinson, 2014, International journal of geriatric psychiatry.

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Jennifer G. Robinson, J. Robinson, 2013, Journal of managed care pharmacy : JMCP.

Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes

Jennifer G. Robinson, K. Yaffe, J. Robinson, 2014, Neurology.